Pharmaceutical Executive: March 2023

As the life sciences industry enters this next stage of growth, capitalizing on AI and digital transformation will be key to propelling innovation and ensuring that companies are prepared to tackle the challenges ahead.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

The importance of not over-expanding during development, launch.

Global medical affairs teams seek better support to manage relationships with key opinion leaders—and find that balance between patient needs, scientific objectives, and the interest areas of KOLs.

How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?

The rise of DOLs doesn’t mean pharma should upend KOL approach.

Chronicling Davidek Herron’s career crossover from playing professional basketball to leading Roche’s digital transformation and scale-up efforts—and the team lessons learned along the way.

Is stock market outperformance for biotech still in the cards for 2023?

How platforms like ChatGPT could transform engagement models.

Region’s diversity plays against efforts to curtail counterfeit drugs.

New candidates are targeting cancer, infectious diseases, and RSV.

While KOLs have been present in healthcare marketing for some time, DOLs are now emerging.

Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.